Guida Maurizio, Castaldi Maria Antonietta, Rosamilio Rosa, Giudice Valentina, Orio Francesco, Selleri Carmine
Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
Ph. D. Program in Translational Medicine, Department of Experimental Medicine, Second University of Naples, Naples, Italy.
J Ovarian Res. 2016 Nov 1;9(1):72. doi: 10.1186/s13048-016-0279-y.
In 1963 George Mathé announced to the world that he had cured a patient of leukaemia by means of a bone-marrow transplant. Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT) is considered the most effective treatment of numerous severe haematological diseases. Gynaecological complications in HSCT women represent a serious concern for these patients, but often underestimated by clinicians in the view of Overall Survival. The main gynaecological complications of HSCT are represented by: premature ovarian failure (POF), thrombocytopenia-associated menorrhagia, genital symptoms or sexual problems in course of chronic GVHD (cGVHD), osteoporosis, secondary solid tumours due to immunosuppressive drugs to treat cGVHD and severity of cGVHD, and fertility and pregnancy issues. In particular fertility-related issues are always more relevant for patients, whose life expectation is constantly growing up after HSCT.Thus, taking care of a patient undergoing HSCT should primarily include gynaecological evaluation, even before conditioning regimen or chemotherapy for the underlying malignancy, as, in our opinion, it is of great importance to ensure a complete diagnostic work-up and intervention options to guarantee maximum reproductive health and a better quality of life in HSCT women.The present review aims at describing principal features of the aforementioned gynaecological complications of HSCT, and to define, on the basis of current international literature, a specific protocol for the prevention, diagnosis, management and follow-up of gynaecological complications of both autologous and heterologous transplantation, before and after the procedure.
1963年,乔治·马瑟向全世界宣布,他通过骨髓移植治愈了一名白血病患者。从那时起,已经取得了很大进展,如今造血干细胞移植(HSCT)被认为是治疗众多严重血液疾病的最有效方法。HSCT女性患者的妇科并发症是这些患者的一个严重问题,但鉴于总体生存率,临床医生往往对此估计不足。HSCT的主要妇科并发症包括:卵巢早衰(POF)、血小板减少相关的月经过多、慢性移植物抗宿主病(cGVHD)过程中的生殖器症状或性问题、骨质疏松症、用于治疗cGVHD的免疫抑制药物导致的继发性实体瘤以及cGVHD的严重程度,以及生育和妊娠问题。特别是与生育相关的问题对患者来说总是更加重要,因为HSCT后患者的预期寿命在不断增加。因此,对接受HSCT的患者进行护理应主要包括妇科评估,甚至在针对潜在恶性肿瘤进行预处理方案或化疗之前,因为在我们看来,确保全面的诊断检查和干预选择对于保证HSCT女性的最大生殖健康和更好的生活质量非常重要。本综述旨在描述HSCT上述妇科并发症的主要特征,并根据当前国际文献,为自体和异体移植前后妇科并发症的预防、诊断、管理和随访制定具体方案。